Brief: Mendus Announces Positive Survival Data From Phase 2 Advance Ii Trial Evaluating Vididencel As Maintenance Therapy For Aml At Ash 2023

Mendus AB (publ)

11/12/2023 18:32

Dec 11 (Reuters) - Mendus AB (publ)  IMMUN.ST :
    * REG-MENDUS ANNOUNCES POSITIVE SURVIVAL DATA FROM PHASE 2
ADVANCE
II TRIAL EVALUATING VIDIDENCEL AS MAINTENANCE THERAPY FOR AML AT
ASH 2023
    * MEDIAN OVERALL SURVIVAL (MOS) WAS NOT REACHED, WITH
MAJORITY OF
PATIENTS (14/20) STILL ALIVE
    * REDUCTION IN MEASURABLE RESIDUAL DISEASE (MRD) AND
INDUCTION OF
IMMUNE RESPONSES CORRELATE WITH RFS AND OS BENEFIT

Source text for Eikon:  ID:nGNE30kY3T 
Further company coverage:  IMMUN.ST 

 ((Reuters.Briefs@thomsonreuters.com;))